Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma has signed an exclusive license agreement with Abic Marketing (Teva), a group subsidiary of Teva Pharmaceutical Industries, for Sitavig commercialization rights in Israel.
Subscribe to our email newsletter
The agreement included upfront and milestone payments as well as royalties on sales in Israel, to be paid to BioAlliance by Teva.
Financial terms of the license agreement were kept confidential.
BioAlliance CEO Judith Greciet said the license agreement with Teva is a major step for Sitavig as it acknowledges the interest and the commercial potential of the product.
"Teva as the leading player on Israeli market is a key partner for BioAlliance and for the commercialization of Sitavig, and we look forward to build a constructive and close partnership," Greciet added.
BioAlliance Pharma developed Sitavig to treat recurrent labial herpes in immunocompetent patients presenting more than four episodes a year.
Sitavig, leveraging mucoadhesive buccal technology Lauriad, delivers high concentrations of acyclovir at the site of herpes infection.